Key result
Pharmacodynamic genetic variants KCNE1-D85N and KCNE2-T8A had definitive and strong evidence, respectively, for association with drug-induced long QT syndrome.
Why the study?
Genetic variants in pharmacodynamic genes have been associated with drug-induced long QT syndrome, but the strength of the evidence for each variant had not yet been evaluated.
What is the strength of evidence for pharmacodynamic genetic variants associated with drug-induced long QT syndrome?
What is the strength of evidence for pharmacodynamic genetic variants associated with drug-induced long QT syndrome?
The genetic variants KCNE1-D85N and KCNE2-T8A have definitive and strong evidence as risk factors for drug-induced long QT syndrome, supporting their consideration before prescribing QT-prolonging drugs.
Evidence for diLQTS variants remains variably graded; leaves open pharmacogenomic testing in practice pending validation.
Drug-induced long QT syndrome (diLQTS) is an adverse effect of many commonly prescribed drugs, and it can increase the risk for lethal ventricular arrhythmias. Genetic variants in pharmacodynamic genes have been associated with diLQTS, but the strength of the evidence for each of those variants has not yet been evaluated. Therefore, the purpose of this review was to evaluate the strength of the evidence for pharmacodynamic genetic variants associated with diLQTS using a novel, semiquantitative scoring system modified from the approach used for congenital LQTS. KCNE1-D85N and KCNE2-T8A had definitive and strong evidence for diLQTS, respectively. The high level of evidence for these variants supports current consideration as risk factors for patients that will be prescribed a QT-prolonging drug.
No takes yet. Share an insight, caveat, or question.
Lopez-Medina et al. (2022) conducted a review in Drug-induced long QT syndrome (diLQTS). Pharmacodynamic genetic variants (KCNE1-D85N and KCNE2-T8A) was evaluated on Strength of evidence for association with diLQTS. Pharmacodynamic genetic variants KCNE1-D85N and KCNE2-T8A had definitive and strong evidence, respectively, for association with drug-induced long QT syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: